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N-hydroxysuccinimideAn intriguing feature ofmitochondrial complex I from several species is the so-called A/D transition, whereby the
idle enzyme spontaneously converts from the active (A) form to the de-active (D) form. The A/D transition plays
an important role in tissue response to the lack of oxygen and hypoxic deactivation of the enzyme is one of
the key regulatory events that occur in mitochondria during ischaemia. We demonstrate for the ﬁrst time that
the A/D conformational change of complex I does not affect themacromolecular organisation of supercomplexes
in vitro as revealed by two types of native electrophoresis. Cysteine 39 of the mitochondrially-encoded ND3
subunit is known to become exposed upon de-activation. Here we show that even if complex I is a constituent
of the I + III2 + IV (S1) supercomplex, cysteine 39 is accessible for chemical modiﬁcation in only the D-form.
Using lysine-speciﬁc ﬂuorescent labelling and a DIGE-like approach we further identiﬁed two new subunits
involved in structural rearrangements during the A/D transition: ND1 (MT-ND1) and 39 kDa (NDUFA9).
These results clearly show that structural rearrangements during de-activation of complex I include several
subunits located at the junction between hydrophilic and hydrophobic domains, in the region of the qui-
none binding site. De-activation of mitochondrial complex I results in concerted structural rearrangement
of membrane subunits which leads to the disruption of the sealed quinone chamber required for catalytic
turnover.
Crown Copyright © 2014 Published by Elsevier B.V. All rights reserved.1. Introduction
Production of energy in most aerobic cells is provided by the joint
activity of the mitochondrial respiratory chain and ATP-synthase.
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r B.V. All rights reserved.catabolism, is oxidised by complex I or NADH:ubiquinone oxidoreduc-
tase [1], the ﬁrst energy converting enzyme in mitochondria. Complex
I catalyses the oxidation of matrix nucleotides by membrane ubiqui-
none and represents the major entry point for reducing equivalents
into the respiratory chain. In contrast to the 14 subunit bacterial en-
zyme, mitochondrial complex I contains 30 additional ‘accessory’ sub-
units of which most have as yet unassigned functions [2]. Complex I
redox centres (FMNand FeS clusters) are locatedwithin the hydrophilic
domain of the L-shaped enzyme molecule, whilst proton translocation
could be carried out by several Na+/H+ antiporter-like subunits in the
membrane arm. The exactmechanisms of energy transduction between
the redox reaction at the terminal cluster N2 and proton translocation in
themembrane part are still not known. Recent studies [3,4] have signif-
icantly improved our understanding of the structure, theproton translo-
cation machinery [4,5] and assembly of complex I [6] but many aspects
of the enzyme's regulation require elucidation.
An intriguing feature of mitochondrial complex I from several verte-
brate species and yeast is the existence of two functionally and structur-
ally different states of the enzyme: active, A-form and de-active or
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(SMP) or puriﬁed complex I as prepared is composed of a mixture
of the A- and the D-forms and requires activation before kinetic
measurements. In the presence of NADH and ubiquinone the D-form
of complex I can be converted back to the A-form as a result of slow
(4 min−1 at 25 °C) catalytic turnover(s) [8]. Non-activated, heteroge-
neous preparations of mitochondrial membranes show a lag phase
during continuous assay of NADH oxidation. After complete activa-
tion, complex I catalyses rotenone-sensitive oxidation of NADH
with a fast linear rate of around 104 min−1 [7]. These catalytically
and structurally distinct forms of the enzyme have been identiﬁed
in puriﬁed preparations in vitro, in cells, as well as in heart ex vivo
in ischaemia [9–13].
Until now, the only known conformational difference between
the A- and D-forms of mitochondrial complex I was the exposure
of cysteine 39 (Cys-39) of the mitochondrially encoded ND3 sub-
unit in the D-form [14]. Covalent modiﬁcation of this critical thiol
renders the D-form sensitive to SH-reagents (NEM and DTNB)
[14,15] and to natural effectors such as nitrosothiols [13,16] and
ROS [12].
This cysteine of the ND3 subunit (homologous to Ser-46 of NqoA in
Thermus thermophilus) is located in a hydrophilic interhelical loop that
connects transmembrane segments (TMS) 1 and 2 and that forms part
of a solvent-inaccessible ubiquinone reaction chamber. The formation
of different semiquinone species as intermediates of electron transfer
in complex I [17–19] probably occurs in this chamber as a result of
sequential reduction of the substrate ubiquinone molecule. It should
be noted, that no semiquinone signal has been observed in the D-form
of complex I [20].
The function of the A/D transition is currently under discussion [21].
When respiration rate is decreased in situ, e.g. at limited oxygen concen-
tration, the turnover of complex I becomes limited due to the lack of
oxidised ubiquinone. This promotes de-activation of the enzyme in
the minute timescale as observed in highly metabolising tissues such
as heart or brain and could be a key event in determining the outcome
of ischaemia/reperfusion [11–13]. A detailed characterisation of the
differences between the two forms would enable better understanding
of the role and mechanisms of the A/D transition. Using two homoge-
nous preparations of bovine heart SMP containing either the A- or the
D-form of complex I, we identiﬁed conformational differences between
the two states. We found that Cys-39 is exposed in the D-form of the
enzyme even when complex I was a part of a respiratory chain
supercomplex. Further, exposed primary amines in complex I were
labelledwith ﬂuorescent NHS-esters and a difference gel electropho-
resis (DIGE) approach was implemented to compare ﬂuorescent
maps of the two forms of the enzyme. The NADPH-containing
subunit 39 kDa (NDUFA9) [22] and the mitochondrially encoded
subunitsND1 (MT-ND1) andND3 (MT-ND3)were found to bemore ex-
posed in the D-form.2. Materials and methods
2.1. Materials
All chemicals were purchased from Sigma-Aldrich, Cy5-
maleimide, Cy3-NHS ester and Cy5-NHS ester were supplied by
Amersham (Amersham CyDye™monoreactive NHS Esters), digito-
nin was purchased from Serva and molecular weight ladder was
from Fermentas.2.2. Mitochondrial preparation and SMP isolation
Bovine heart SMP were prepared according to standard procedure
[9] and stored in liquid nitrogen.2.3. Activity measurements
Oxidation of NADH was determined spectrophotometrically
(Varian Cary® 3000) as a decrease in absorption at 340 nm (ε340nm =
6220 M−1·cm−1) with 165 μMNADH in SET medium (0.25 M sucrose,
0.2 mM EDTA, 50 mM Tris–HCl, pH 7.0) or PBS pH 7.0 buffer containing
SMP (10–25 μg of protein/ml). Alternatively, complex I NADH:Q1 oxido-
reductase activity was assessed: 25 μg SMP were diluted in 1 ml PBS
pH 7.5 supplemented with 10 μM NADH to convert the enzyme to the
A-form. 1 mM KCN, 30 μM Q1 and 165 μM NADH were then added to
the suspension and the NADH oxidation ratewasmeasured in the linear
part of the curve.
The A/D ratio in each sample was estimated essentially as in [12]
by measuring the initial rate of NADH oxidation at 340 nm. SMP
(25 μg) were either directly added to 1 ml of measuring buffer (SET
or PBS pH 8.8 supplemented with 165 μM NADH and 2 mM MgCl2)
or incubated with 15 μM NADH at pH 7.2 prior to further dilution
in measuring buffer. The measured rates correspond respectively to
the activity of only the A-form and the total activity of complex I,
i.e. the activity after NADH-dependent conversion of all complex I
to the A-form.
2.4. Preparation of A- and D-forms of complex I
To prepare SMP in which complex I is converted to the D-form,
SMP were resuspended to 5 mg/ml in SET or PBS buffers pH 8.0
supplemented with 1mMmalonate and 5mMMgCl2 and incubated
at 35 °C for 30–60 min under constant shaking. This treatment re-
sulted in almost complete deactivation of complex I. The resulting
sample was then divided in two equal parts, one was kept on
ice (D-form) and the other was aerobically re-activated in the
presence of 400 μM NADH and a NADH regenerating system
(0.1 mg/ml alcohol dehydrogenase from Saccharomyces cerevisiae,
1% ethanol) for 20 min at room temperature with constant stirring
[16]. This treatment resulted in full activation and maintained
complex I in the A-form.
2.5. Treatment with covalent reagents
The effects of amino-acid speciﬁc reagents were evaluated by
measuring the NADH:Q1 oxidoreductase activity as described
above. The effects of these reagents on the D-form were assessed
by measuring activity of the treated D-form after NADH-dependent
activation.
Sulfhydryl groups were labelled as described previously [14] with
minor modiﬁcations. Pelleting was performed by centrifugation at
20,000 g at 4 °C for 30 min. SMP were diluted to 5 mg/ml in SET buff-
er pH 7.5 and complex I was activated in the presence of an NADH-
regenerating system. SMP containing the A-form of complex I were
then incubated with 30 mM NEM at 15 °C for 15 min. After thiol
blockage the reaction was terminated by the addition of 3 volumes
of SET buffer pH 7.5 supplemented with 35 mM cysteine. SMP were
washed twice in SET buffer pH 7.5. The sample was split into two
portions prior to the penultimate centrifugation step. One portion
was kept on ice (NEM-treated A-form) and the other one was de-
activated (NEM-treated D-form). Both samples were resuspended
at 5 mg/ml in SET buffer pH 7.5 and treated with 2 μM Cy5-
maleimide at 15 °C for 15 min in the dark. Labelled SMP were then
collected by centrifugation and samples were immediately prepared
for a BN-PAGE analysis.
For tyrosine labelling, SMP containing A- or D-forms of complex
I were diluted to 5 mg/ml and treated with 2 to 15 μM of
tetranitromethane (TNM) in SET buffer pH 8.0 prior to activity mea-
surements or incubated with 3 mM N-acetylimidazole (NAI) in PBS
pH 7.2. For NAI, the reaction was conducted at pH 7.2, which maintains
a good balance between the rate of the reaction and the stability of the
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assessed by incubation with 1 mM DTT after treatment with 15 μM
TNM or with 100 mM of hydroxylamine after a 1 hour incubation
with 3 mM NAI.
For lysine labelling, SMP containing A- or D-forms of complex I
were diluted in PBS pH 7.4 [24] to 10 mg/ml and incubated with
10 μM Cy5-NHS esters for 1 h at 10 °C. The reaction was terminated
by 10 minute incubation on ice with 50 mM Tris–HCl pH 7.0. Labelled
proteins were then immediately prepared for BN-PAGE analysis.
For activity measurements, SMP containing A- or D-forms of
complex I were diluted to 1 mg/ml in PBS pH 7.4 and incubated
with 8 μM of ﬂuorescein-NHS (F-NHS) for 1 h at 10 °C in the dark.
Aliquots were taken every 10 min to measure the NADH:Q1 oxidore-
ductase activity.
2.6. Cy3-NHS and Cy5-NHS esters labelling (DIGE)
SMP containing A- or D-forms of complex I were diluted to
1 mg/ml in PBS pH 7.4 and incubated for 1 h at 10 °C in the presence
of 8 μM of either Cy3-NHS ester or Cy5-NHS ester. The reaction was
stopped by a 10 minute incubation on ice with 50 mM Tris–HCl
pH 7.0. The suspension was then centrifuged at 20,000 g for
20 min at 4 °C and pellets were prepared for BN-PAGE analysis. Pro-
teins were extracted with 2.5 g of DDM per gram of protein and
Cy3/Cy5-labelled samples mixed to a 1:1 ratio (wt/wt). Complex I
was isolated on a 4–13% BN-PAGE and differentially labelled subunits
from both A- and D-forms were separated with double SDS-PAGE
(dSDS-PAGE).
2.7. BN-PAGE/dSDS-PAGE analysis
The SMP pellet was processed according to [25] using DDM or
digitonin at a ratio of 2.5 g or 6 g of detergent per gram of protein,
respectively. Solubilised SMP (150–300 μg of protein) were applied
on a 4–13% gradient BN-PAGE. For hrCN-PAGE, a cathode buffer
(50 mM tricine, 7.5 mM imidazole, pH 7) supplemented with
0.01% DDM and 0.05% deoxycholate was used [26]. The complex I
band was excised from BN-PAGE and dSDS-PAGE (10% SDS-PAGE
supplemented with 6 M urea for the ﬁrst dimension, 16% SDS-
PAGE for the second) was performed [14,27]. Gels were then
scanned for ﬂuorescence with λex/λem 635/670 nm for Cy5-NHS
and 532/580 nm for Cy3-NHS using a ﬂuorescence image scanner
(FLA-7000, Fujiﬁlm Life Science) and silver-stained as described
previously [28].
2.8. Fluorescence analysis
Fluorescent scans were analysed with AIDA Image Analyzer
(Raytest). For each set of experiments, the intensity of each spot
was automatically quantiﬁed by the software and the background
was subtracted from the signal for each spot. The intensity of ﬂuo-
rescence was then expressed as a percentage of the total ﬂuores-
cence of all protein spots in the gel. This last step is a prerequisite
for comparison since the dyes used do not have the same quantum
yield (0.28 for Cy5 and 0.15 for Cy3). A- and D-form samples were
both treated with Cy3 and Cy5-NHS esters and measures of all four
signals were taken into account to overcome dye-dependent effects
for quantiﬁcation.
2.9. Mass spectrometry analysis
Gel spots from CyDye NHS treated A- and D-forms were excised and
cut into 1 mm cubes. These were then subjected to in-gel digestion,
using a ProGest Investigator in-gel digestion robot (Genomic Solutions,
Ann Arbor, MI) using standard protocols [29]. Brieﬂy the gel cubes were
destained by washing with acetonitrile and subjected to reduction andalkylation before digestion with trypsin at 37 °C. The supernatant was
collected and then the gel pieces extracted twice with 50% acetonitrile,
5% formic acid and then twice with 95% acetonitrile, 5% formic acid
and the combined extracts concentrated to 20 μl using a SpeedVac
(ThermoSavant).
The peptideswere then separated using a nanoLCUltra 2Dplus load-
ing pump and nanoLC as-2 autosampler equipped with a nanoﬂex
cHiPLC chip based chromatography system (Eskigent), using a ChromXP
C18-CL trap and column. The peptides were eluted with a gradient of
increasing acetonitrile, containing 0.1% formic (5–40% acetonitrile in
5 min, 40–95% in a further 1 min, followed by 95% acetonitrile to clean
the column, before reequilibration to 5% acetonitrile). The eluent was
sprayed into a TripleTOF 5600 electrospray tandem mass spectrometer
(ABSciex, Foster City, CA) and analysed in Information Dependent
Acquisition (IDA) mode, performing 250 ms of MS followed by 100 ms
MSMS analyses on the 20 most intense peaks seen by MS. The MS/MS
data ﬁle generatedwas analysed using the ProteinPilot 4.5 Paragon algo-
rithm (ABSciex) against the Swiss-Prot database Jan 2013 with no spe-
cies restriction, trypsin as the cleavage enzyme and carbamidomethyl
modiﬁcation of cysteines.
TNM treated active/de-active forms of complex I were isolated
by BN-PAGE and subunits were separated by dSDS-PAGE. Spots
containing the ND3 subunit were treated with DTT and cysteines
were carbamidomethylated with iodoacetamide. This was followed
by in-gel digestion with trypsin. Tryptic peptides were subjected to
LC–MS/MS analysis on an LTQ-Orbitrap XL (Thermo) mass spec-
trometer coupled to a nano-HPLC (Agilent). Brieﬂy, peptides were
separated in 30 min on an in-house C18 nano-ﬂow column with
an acetonitrile gradient (5–45%) containing 0.1% formic acid. This
was followed by cleaning with 95% acetonitrile and reequilibration
with 5% acetonitrile (15 min each step). Collision induced dissocia-
tion (CID) spectra were collected and evaluated by Mascot data-
base searches against UniProt database of Bos taurus (26,536
sequences January 2012) with optional modiﬁcations on cysteine
by carbamidomethylation, mono-, di- and tri-oxidations, modiﬁca-
tion by acrylamide, mono-oxidation onmethionine and nitration of
tyrosine.
Label free quantiﬁcation was conducted using Proteome Discoverer
1.3 Precursor Ions Area Detector node (Thermo Fisher scientiﬁc).
3. Results
3.1. The supercomplex proﬁle after separation by native electrophoresis is
not affected by de-activation of complex I
Complex I is found to be a member of several supercomplexes as
revealed by native electrophoresis after solubilisation of mitochon-
drial membranes with digitonin; amild detergent known to preserve
oligomeric association between membrane proteins [25]. Several
different higher molecular weight forms can be observed after sepa-
ration on a gradient native gel [26]. In such supercomplexes, com-
plex I is either associated with complex IV (I + IV), with two
copies of complex III (I + III2), two copies of complex III and several
copies of complex IV (I + III2 + IVx) [26].
To date, mitochondrial complex I is the only enzyme of the mi-
tochondrial respiratory chain known to undergo a so called A/D
conformational change. Whether the association of this enzyme
with other complexes is inﬂuenced by its conformation remains
unclear.
The supercomplex proﬁles of SMP containing A- or D-form complex
I were analysed after separation by native electrophoresis. After label-
ling with a ﬂuorescent lysine-reactive reagent, Cy5-NHS ester, A- and
D-forms were solubilised and applied on a 4–13% BN-PAGE (Fig. 1A).
No differences in Coomassie staining, complex I in-gel activity or ﬂuo-
rescent signal were detected between the two samples (Fig. 1A, lanes
1 to 3). Complex I from both A- and D-forms migrated at the same
Fig. 1. Effect of deactivation of complex I on the supercomplex proﬁle of bovine heart mitochondrial membranes. SMP containing the A- or the D-form of complex I were treated
with Cy5-NHS ester as described in Materials and methods. Membranes were solubilised with digitonin and 150 μg of protein for each sample were applied on a 4–13% BN-PAGE
(A) or hrCN-PAGE (B). Proteins were visualised by Coomassie Blue staining (lane 1), complex I in-gel activity staining (lane 2) or ﬂuorescent labelling (lane 3). Here and below
complexes are labelled according to [26]. I, II, III and IV stand for mitochondrial respiratory complexes I–IV; ATPase for F1–Fo ATP synthase; I/IV for the association of complexes I
and IV. S0 for respiratory supercomplex I + III2 and S1 for I + III2 + IV. (C) Silver stained 2D gels (10% SDS-PAGE supplemented with 6 M urea) of supercomplexes S1, S0, I/IV and
complex I isolated from SMP containing the A or D-form of complex I.
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D-forms. In-gel activity staining (Fig. 1A, lane 2) revealed four bands
corresponding to complex I alone and three types of association
with other complexes (I/IV; I + III2; I + III2 + IV) independent of
its conformational state.
Since Coomassie in BN-PAGE quenches ﬂuorescent signals
[26,30] samples were also subjected to hrCN-PAGE to test whetherFig. 2. Accessibility of Cys-39 from the ND3 subunit of complex I in the S1 supercomplex to chem
divided equally into two parts and one part was de-activated. Both the A and D formswere labe
section. (A)Mitochondrialmembrane proteinswere solubilisedwith digitonin and themitocho
stainedwith Coomassie Blue. (B) In-gel activity staining of complex I was performed and bands
to a 10% SDS-PAGE + 6 M urea. (C) Representative in gel ﬂuorescence scan after subunit sep
denoted on the left, the black arrow indicates the ND3 subunit (13.1 kDa).supercomplex and subcomplex proﬁles remained the same for both
samples with more sensitive detection (Fig. 1B). Complex I was in-gel
activity stained whilst Coomassie staining and ﬂuorescent labelling was
used to observe all respiratory chain components. No differences in mi-
gration proﬁle were detected. Since a small variation in the composition
of these supercomplexes could not easily be detected on BN/CN-PAGE,
a second denaturing electrophoresis was run in order to separate theical modiﬁcation. A-form of complex I in SMPwas treatedwith NEM. The suspension was
lled with NEM and incubated with Cy5-maleimide as described inMaterials andmethods
ndrial complexes and supercomplexes (150 μg of protein)were separated by BN-PAGE and
S1 (complex I as part of supercomplex I+ III2+ IV) and I (complex I alone)were subjected
aration on the second denaturing dimension. Approximate molecular weights (kDa) are
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composition of the supercomplexes containing A andD forms of complex
I was similar.
Taken together these results suggest that the A/D conformational
change(s) of complex I has no effect on the association of the
enzyme with other respiratory chain complexes in vitro as revealed
by native electrophoresis. The A/D transition has no effect on the
subunit composition of complex I, conﬁrming our previous study
[14]. Here we have demonstrated that the A/D transition does not
modify the three different supercomplex forms with which complex I is
associated.
3.2. Cys-39 of the ND3 subunit remains accessible in supercomplexes
SH-reagents such as N-ethylmaleimide (NEM) are known to cova-
lently modify Cys-39 of the ND3 subunit in the D-form of the enzyme
[14,31]. Once associated in its D-formwith other respiratory complexes
(i.e. complex III and complex IV), this cysteine could be enclosed and
inaccessible to modiﬁcation due to steric hindrance. We testedwhether
this cysteine is accessible to covalent modiﬁcation if the D-form of
complex I is a constituent of a supercomplex after solubilisation with
digitonin.
Using the labelling strategy developed previously [14], the A-formof
complex I in SMP was treated with NEM to block available cysteine
residues. One part of the sample was then de-activated and both A- and
D-formswere treatedwith ﬂuorescein-NEM in order tomodify residues
only exposed in the D-form. Proteins were then separated by BN-PAGE,
bands corresponding to complex I alone (band I, Fig. 2A and B) and S1
supercomplex (I + III2 + IV, Fig. 2A and B) were excised and subunits
were separated in denaturing conditions. As previously shown [14],
Cys-39 of the 13.1 kDa subunit ND3 is the only cysteine residue differ-
entially labelled when complex I was separated by BN-PAGE (Fig. 2C,
I). The same ﬂuorescent pattern was observed when complex I was
part of the S1 supercomplex (Fig. 2A, B). These results suggest that, in
the D-form of complex I, Cys-39 of the ND3 subunit is accessible for
covalent modiﬁcation independently of its possible association with
complexes III and IV.
3.3. The D-form of complex I is highly sensitive to tyrosine reactive reagents
We used a different type of chemical modiﬁcation that speciﬁcally
targets other amino acids to gain further insight into the structural dif-
ferences between these two conformations. Tyrosine-speciﬁc reagents
have beenwidely used to demonstrate the importance of these residues
for a protein's function [32]. Two types of reagent were used to assess
any differential accessibility of complex I subunits depending on itsFig. 3. Effect of tyrosine speciﬁc reagents onNADH:Q1 activity of the A- andD-forms of complex
TNM and NADH:Q1 reductase activity measured as described in the Materials and methods sec
regular intervals during 60min; (B) reversibility of NAImodiﬁcationswas assessed by incubatio
ing concentrations of TNMand activitymeasured. Reversibility of TNMmodiﬁcationwas assesse
samples. 100% activity corresponds to 1 μmol of NADH·min−1·mg−1 of protein. Data are meaconformation. NAI O-acetylates protein tyrosyl residues at a pH
close to neutral and TNM nitrates these residues in mildly alkaline
conditions. As shown in Fig. 3A, the A-form remained active after
treatment with NAI, losing only 15% of its activity after a 1 hour incu-
bation, whereas the D to A conversion of the D-formwas inhibited by
73%. NAI can also react with other residues, including cysteines via
sulfhydryl oxidation [32]. Since hydroxylamine deacetylates labile
acetyl groups, it was used to assess selective removal of the tyrosine
modiﬁcation. The reducing treatment with hydroxylamine resulted
in almost full recovery of the NADH:Q1 reductase activity (Fig. 3B).
Therefore we concluded that tyrosine modiﬁcation was the main re-
sult of the enzyme treatment with NAI. The modiﬁcation by NAI is not
stable and hydrolysed spontaneously after 4 h (data not shown). In order
to determine which modiﬁed tyrosine residues could be responsible for
the inhibition of the D-form, a stable modiﬁcation was a prerequisite.
The modiﬁcation of protein tyrosine residues with TNM is known to be
stable over a long enough timescale to allow the identiﬁcation of modi-
ﬁed sites bymass spectrometry [33]. As shown in Fig. 3C, TNM treatment
of the D-form led to inhibition of its re-activation, whilst the A-form
remained fully active even at high TNM concentration. The speciﬁci-
ty of the reaction with TNMwas assessed by treatment with DTT that
would reduce reversibly oxidised cysteines. DTT did not recover
TNM inhibition of the D-form, indicating that tyrosine(s) were
targeted or cysteines were overoxidised to sulﬁnic or sulfonic acid.
As the inhibition of reactivation of the D-form with TNM appeared
to ﬁt the proﬁle of NEM inhibition previously observed [14], ND3
was analysed by mass spectrometry. However a nitration of the
tyrosine residue in the identiﬁed ND3 peptide (TSPYECGFDPMGSAR)
was not detected. Interestingly, Cys-39 in the TNM treated D-form
was found to be 14 times more overoxidised compared with the A-form
(Table 1 and Fig. A1). Since trioxidation on cysteine is not reduceable by
DDT, this thiol modiﬁcation could prevent the re-activation of complex I
in the D-form in the presence of DTT.
The irreversible chemical modiﬁcation of Cys-39 of the ND3 subunit
in the D-form of complex I could then account for the inhibition of the
re-activation observed with TNM. However, with the NAI treatment
being almost fully reversible, as observed with hydroxylamine, it is
unlikely that Cys-39 would be targeted.
A systematic analysis of the 44 subunits of complex I would be nec-
essary to identify the bulk of TNM-modiﬁed residues and thedifferences
between the modiﬁed A- and D-forms of complex I with mass spec-
trometry [33] and/or western-blot using antibodies directed towards
nitro-tyrosine.
Here, we used a faster method with ﬂuorescent reagent in order
to directly identify any subunits involved in conformational changes
between the A- and D-forms of complex I.I in SMP. A-form (circle) or D-form (square) of complex I in SMPwere treatedwith NAI and
tion. (A) SMP were incubated with NAI and NADH:Q1 reductase activity was measured at
n with hydroxylamine (HA) after treatmentwith NAI. (C) SMPwere treatedwith increas-
d by incubationwithDTT. Data are expressed as a percentage of the activity for non-treated
n ± S.D. from 3 independent experiments.
Table 1
Label free quantiﬁcation of the modiﬁed ND3 peptide.
TSPYECGFDPMGSARa A-formb D-formb Ratio D/A Mascot score
A D
C6(carbamidomethyl) 1149961 1590834 1.4 33 65
C6(carbamidomethyl); M11(oxidation) 633153 30
C6(propionamide) 4725446 60
C6(trioxidation) 969553 14305278 14.8 34 46
C6(trioxidation); M11(oxidation) 13997917 61
C6(carbamidomethyl + propionamide) 5875408 1590834 0.3
C6(trioxidation) 969553 14305278 14.8
The two last rows summarise the obtained results for carbamidomethyl + propionamide and trioxidation modiﬁcations of Cys-39.
a Modiﬁcations found on the unique analysed peptide.
b Peptide areas extracted from the HPLC chromatograms with the precursor ions area detector node implemented into the Proteome Discoverer workﬂow.
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exposure of three subunits
In order to identify subunits differentially exposed in the A-form and
the D-form we used lysine-speciﬁc N-hydroxysuccinimide ester based
ﬂuorescent dyes. NHS is known to acylate the primary amino-group
leading to a covalent modiﬁcation of the ε-amino-group of lysine or
the N-terminal amino-group [24,34]. Unlike cysteine, lysine residues
are relatively abundant in proteins permitting the detection of every
subunit of complex I and analysis of their conformation-dependent
exposure. Indeed, lysines in the 44 mammalian complex I subunits
represent around 5.7% of the total number of amino-acids and ND4L,
the smallest mitochondrially encoded subunit, is the only one without
lysine. By comparison, the average cysteine content is only 1.3%, with
12 subunits without any cysteine residue in their sequence. The effect
of lysine modiﬁcation was assessed by NADH:Q1 activity measurement
after F-NHS ester treatment. SMP were incubated with 8 μM of F-NHS
ester, a concentration that permits the labelling of proteins in non-
saturating conditions. In these conditions, activities of both the A- and
D-forms remained unaffected (Fig. 4). Any observed differences in dye
incorporation would indicate a differential exposure of particular sub-
units and not a modiﬁcation of the enzyme structure induced by the
reagent.
A DIGE approach relies on the covalent labelling of two or more
samples with a chemical compound bearing the same reactive partFig. 4. Effect of lysine-speciﬁc reagents on the NADH:Q1 activity of the A and D forms of
complex I in SMP. A-form (circle) or D-form (square) of complex I in SMP was treated
with a ﬂuorescent lysine-targeting reagent (F-NHS). Aliquots were taken at regular time
intervals and the reactionwas terminated by 50mMTris–HCl pH7.0 and NADH:Q1 reduc-
tase activity measured. 100% corresponds to 1 μmol of NADH·min−1·mg−1 of protein.
Data are mean ± S.D. from 3 independent experiments.and a ﬂuorophore with different spectral properties. After treat-
ment, samples are combined and separated by denaturing electro-
phoresis. This mixing step circumvents the problem of variability
between gels. The A- and D-forms of complex I in SMP were la-
belled either with cyanine ﬂuorescent Cy3-NHS or Cy5-NHS esters
respectively and pooled. Subunits were then separated by dSDS-
PAGE (Fig. 5). A reciprocal experiment where A-form was labelled
with Cy5-NHS and D-form with Cy3-NHS was also performed.
Results of ﬂuorescent intensity quantiﬁcation with both dyes for
each form of complex I (i.e. A-Cy3-NHS + D-Cy5-NHS and A-Cy5-
NHS + D-Cy3-NHS) are presented in Fig. 5B. Three subunits identi-
ﬁed by mass spectrometry (Table A1) were found to be differential-
ly labelled and more exposed in the D-form of complex I. ND3
subunit signal is 4 fold higher in the D-form than in the A-form of
complex I. This observation was consistent with earlier reports
that showed exposure of Cys-39 of this subunit in the D-form only
[14] and validated our approach. Two other subunits were found
differentially exposed depending on the conformation of the en-
zyme. Indeed, 39 kDa (NDUFA9) and ND1 were found to be 1.7
and 2 fold more labelled in the D-form, respectively (Fig. 5B). The
39 kDa subunit is an accessory subunit of mammalian complex I,
whereas ND1 is a mitochondrially encoded core subunit involved
in proton translocation [4].
For the ﬁrst time, we demonstrate that ND3 is not the only subunit
to become exposed upon deactivation of mitochondrial complex I. A
second membrane subunit, ND1 and the accessory subunit 39 kDa are
shown to be associated with the structural reorganisation leading to
the D-form of the enzyme.
Protein labelling with NHS esters leads to the elimination of tryptic
cleavage sites [35] as trypsin mainly cleaves at the carboxyl side of
lysine and arginine residues [36]. Membrane proteins, such as ND3
and ND1, are not easily detected by mass spectrometry, preventing
us from estimating the region(s) differentially exposed due to a low
number of detectable peptides (Table A1). The 39 kDa subunit, thought
to have only one TMS [37], was the main candidate for comparison of
tryptic peptide proﬁles from the A- and D-forms of complex I. The
higher the number of peptides detected the higher the probability of
detectingmissed cleavage sites to conﬁrm a different degree of labelling
between A- and D-forms.
This subunit has 44 theoretical tryptic peptides (PeptideMass
Expasy, SwissProt accession number P34943). Among them, 28 are
generated by a cleavage after lysine residues (Fig. 6). Lys 113 is the
only lysine residue for which no peptides were matched to 39 kDa in
both A- and D-forms (Fig. 6). Six missed cleavage sites of 39 kDa from
the D-form of complex I were reported (Fig. 6). These residues were
all observed/cleaved in the A-form. It is therefore conceivable that the
difference in the ﬂuorescent intensity between A- and D-forms of com-
plex I for the 39 kDa subunit corresponds to a modiﬁcation at Lys-45,
163, 233, 318, 327 and 348.
Fig. 5. Fluorescent labelling of A- and D-forms of complex I with CyDye™monoreactive NHS esters. The A- andD-forms of complex I in SMPwere respectively treatedwith Cy3-NHS ester
and Cy5-NHS ester and subjected to a DIGE-like approach. (A) Complex I was isolated on a 4–13% polyacrylamide gradient BN-PAGE and subunits from A- and D-forms (right and left
panels respectively) were separated by dSDS-PAGE as described in Sections 2.6 and 2.7. Numbers 1, 2 and 3 stand for ND3, ND1 and 39 kDa subunits respectively. (B) Fluorescent inten-
sities were quantiﬁed as described inMaterials andmethods section. The A- and D-forms were both treatedwith Cy3 and Cy5-NHS esters andmeasures of all four signals were taken into
account for the quantiﬁcation. Data are mean ± S.D. from at least 5 independent experiments. *p b 0.01 compared to A-form.
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An intriguing feature of mitochondrial complex I is its ability to
switch from an active (A) form to a de-active (D) form. The role ofFig. 6. Primary sequence of the bovine 39 kDa subunit (NDUFA9). The hydrophobic segment pr
peptides resulting from a cleavage after lysine residues are underlined. The lysine residues are s
for the D-form only are indicated by grey boxes and orange boxes respectively. *Non cleavablethis transition in enzyme regulation and functioning still remains
to be characterised in detail. Despite recent progress detailing the exis-
tence of two forms of mitochondrial complex I in situ [10–13] and the
important role played by the A/D transition in mitochondrial responseedicted to be a transmembrane segment [39] is delineated in green. The theoretical tryptic
hownwith boxeswithmissed lysine cleavage for both A- and D-form andmissed cleavage
lysine as followed by a proline residue.
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differences between the two forms.
The A to D transition of the enzyme in bovine SMP is characterised
by high activation energy [9], suggesting signiﬁcant conformational
changes in complex I upon deactivation. Until now, the only part
of complex I known to be differentially exposed depending on the
A/D conformation is the matrix-facing loop connecting the ﬁrst
and second TMS of the ND3 subunit. Indeed, ND3's single cysteine
(Cys-39, equivalent to Ser-46 of Nqo7 in T. thermophilus) is exposed
to the matrix side in the D-form only, where it is susceptible to cova-
lent modiﬁcation by SH-reagents, nitric oxide metabolites and ROS
[12,14,16,31].
In the present study, we addressed two different questions to
gain additional understanding of the A/D transition: (i) Does the
de-activation of complex I affect the supercomplex assembly? (ii)
Apart from ND3, are there any additional subunits associated with
conformational changes upon de-activation?4.1. The D-form of complex I does not affect supercomplex formation in vitro
Complex I has been proposed as an ‘enhancer’ of supercomplex for-
mation [39–41], suggesting a central role in their assembly/regulation. It
has recently been suggested that MCJ, a methylation-controlled
J protein belonging to the DnaJC subfamily of co-chaperones, could
interact with and negatively regulate mitochondrial complex I. The
presence of this protein would decrease both the formation of
supercomplexes and complex I activity; thus MCJ may play a role in
the regulation of the A/D transition [42]. However, to our knowledge,
the inﬂuence of complex I conformation on the degree of association
with other members of the respiratory chain has never been
examined.
In order to investigate this, the supercomplex proﬁle of SMP
containing the A- or D-forms of complex I were analysed after sep-
aration by two types of native electrophoresis. We did not ﬁnd any
differences in the migration proﬁle and content of supercomplexes
depending on the conformation of complex I. Our data suggests
that the conformation of complex I does not affect the structural
formation or stability of supercomplexes in bovine heart SMP. In-
deed, the fact that no extra bands could be detected with in-gel ac-
tivity staining or highly sensitive ﬂuorescent labelling suggests
that complex I can adopt two different conformations whilst
being part of a higher molecular weight complex. It is important
to note that, unlike NADH:ubiquinone reductase, the commonly
used rotenone-insensitive NADH:tetrazolium reaction for in-gel
activity measurements is catalysed by both forms of the enzyme
with the same rate.
Therefore, the A/D transitionwould correspond to changes in the en-
zyme structure rather than changes of themacromolecular organisation
within supercomplexes.
The D-form of complex I is characterised by the exposure of Cys-39
of the ND3 subunit. Complex I is known to associate with complexes
III and IV. In the S1 supercomplex, the complex III dimer has been
shown to locate in the arc of the bent membrane part of complex I,
allowing the ubiquinone binding sites of both complexes I and III to
face each other [43]. In the D-form, Cys-39 of the ND3 subunit (located
in the vicinity of the ubiquinone binding site [4]) could be masked and
inaccessible to chemical modiﬁcation once associated with respiratory
complexes III and IV. To test this hypothesis, complex I was modiﬁed
with NEM/F-NEM as described in [14]. As expected, we observed ﬂuo-
rescent labelling of ND3 in the separated complex I band. This labelling
was preserved even when complex I was part of the I + III2 + IV
supercomplex. Our result indicates that the potential interaction
between complex I and complex III in the mitochondrial membrane
does not signiﬁcantly affect the accessibility of Cys-39 in the D-form
of the enzyme.4.2. Speciﬁc amino-acid labelling unveils the association of ND1 and 39 kDa
subunits with structural reorganisation upon de-activation
To characterise the other potential differences in the accessibility
of complex I subunits, we decided to test several amino acid speciﬁc
covalent reagents. A- and D-forms of complex I in bovine heart SMP
were treated with tyrosine-speciﬁc reagents, NAI and TNM. These
compounds covalently modify tyrosine residues with a high level of
speciﬁcity. We found that both reagents inhibited the re-activation
of the D-form of the enzyme, suggesting other amino acids are
exposed in the D-form. Modiﬁcation of two tyrosines (Tyr-30 and
Tyr-37) in close proximity to Cys-39 of the ND3 subunit may account
for the sensitivity of the D-form to NAI and TNM. Amass spectromet-
ric analysis of the TNM-modiﬁed ND3 subunit did not permit us to lo-
cate the modiﬁcation site(s) on tyrosine residues [14,44]. However,
the differential exposure of tyrosine residues from other subunits
during the A to D transition cannot be excluded and is currently
under investigation. Besides tyrosine nitration it has been reported
that treatment with TNM alternatively oxidises cysteine. To enhance
the speciﬁcity of TNM treatment for tyrosine nitration NEM can be
added to the labelling mixture [45]. Because cysteine labelling irre-
versibly alters the enzyme, ‘locking’ de-activated complex I in the
D-form, it had to be omitted in order to observe the effects of TNM
only.
This enabled us to identify sulfonic acid modiﬁcation on Cys-39 after
TNM treatment resulting in an irreversible de-activation of complex I.
Since sulfonic acid modiﬁcation could occur in vivo upon oxidative
stress [46] complex I could be arrested in the D-form resulting in com-
plex I deﬁciency.
We used lysine speciﬁc ﬂuorescent NHS-esters combined with a
DIGE-like approach to gain further insight into the structural differences
between these two conformations. We identiﬁed three subunits
that were unequivocally more exposed in the D-form: ND3, ND1 and
39 kDa (NDUFA9).
The differential exposure of theND3 subunit conﬁrmed our previous
results [14] and validated our approach. The bovine ND3 subunit
contains three lysine residues, all of which are potentially accessible
from thematrix side. Lys-33 and Lys-54 belong to the Cys-39 containing
hydrophilic loopwhereas Lys-109 is located in the soluble C-terminus. It
is thus tempting to speculate that Lys-109 is labelled in both forms
whereas Lys-33 and Lys-54 are labelled only in the D-form, accounting
for the difference in the intensity of ﬂuorescence. Taken together
these data may suggest that a signiﬁcant region of the ND3 subunit
(probably between Trp-22 and Lys-54) becomes exposed when com-
plex I undergoes deactivation.
The 39 kDa (NDUFA9) nuclear encoded accessory subunit
was found to be associated with structural rearrangement during
the A/D transition and therefore more accessible for chemical modi-
ﬁcation upon deactivation of complex I. A previous study performed
in our laboratory [44] revealed that ND3 can be crosslinked with
39 kDa subunit by a heterobifunctional \NH2/\SH speciﬁc 6.8 Å
crosslinker only when complex I is in the D-form. This observation
could be accounted for by the individual movement of the hydrophil-
ic loop of ND3 towards 39 kDa subunit or by a combined rearrange-
ment of the two subunits. The work presented here strongly
suggests that 39 kDa subunit undergoes concerted structural rear-
rangement along with ND3 during de-activation. The 39 kDa subunit
is thought to be anchored to the membrane part of the enzyme via a
single hydrophobic transmembrane helix [37] and positioned at
the crucial junction region [47] between the membrane and the
hydrophilic matrix domain of complex I [2,47,48]. This corresponds
to the location of the NqoA subunit (homologous to ND3) in the
T. thermophilus enzyme structure [4,49].
The 39 kDa (NDUFA9) subunit belongs to the family of short-chain
dehydrogenase/reductases. It contains a nucleotide binding Rossmann
fold motif [50] where one molecule of NADPH is non-covalently
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turnover and is present in the reduced form [51,52].
Mutations affecting the NADPH binding site in Yarrowia lipolytica
protein have only aminor effect on the ubiquinone reductase activity
of complex I, suggesting a stabilising function for this nucleotide
rather than a role in biosynthesis of complex I [51]. However, disrup-
tion of this subunit in HEK cells [53,54] or mutation of a highly
conserved arginine [55] results in defective complex I assembly or
neonatal fatality respectively. Taken together, this indicates the
importance of the NDUFA9 subunit for complex I functioning and
regulation.
Another main ﬁnding of this study is that ND1, a core membrane
subunit, is also affected by structural rearrangements upon deactiva-
tion of complex I. The recently obtained three-dimensional structure
of the bacterial enzyme clearly revealed the quinone reaction cham-
ber [4]. This cavity is formed by four different subunits. The ND1 and
ND3 subunits (Nqo8 and Nqo7 in T. thermophilus complex I) form
the cavity at the quinone entrance side, accommodating the hydro-
phobic isoprenoid tail. The 49 kDa and PSST subunits (Nqo4 and
Nqo6 in T. thermophilus complex I) accommodate the quinone head
group from the N2 terminal cluster side [4]. The entry point of this
cavity is delineated by TMS1, TMS6 and AH1 of ND1, as well as
TMS1 from ND3. ND1 and ND3 narrow the entrance of the cavity,
so that when quinone binds, the cavity would be enclosed and sepa-
rated from the bulk solvent. The bovine ND1 subunit has a unique
cysteine (Cys-301) located in TMS8 and facing the matrix side.
Fluorescein-NEM treatment of both the A- and the D-form of complex
I resulted in equal ﬂuorescent labelling of this subunit [14], suggesting
a similar exposure of TMS8 located at the C-terminal extremity.
Among seven lysines found in the bovine ND1 sequence, two are locat-
ed in the vicinity of TMS1 and AH1 of ND1. Based on the T. thermophilus
structure, three other ND1 lysine residues (Lys-54, Lys-58 and Lys-126)
are located within 10 Å of the hydrophilic loop of ND3 [4]. Their expo-
sure could be modiﬁed upon de-activation, and structural rearrange-
ments within this region could potentially account for the differential
labelling observed for ND1.
Mutations in humanMT-ND1 are associated with the appearance of
several severe syndromes, including LHON and MELAS. To date, 41
disease-associated mutations onMT-ND1 have been reported [56]. Most
of thesemutations are located in the hydrophilic loop of ND1 (for review,
see [57]). Studies on themolecular consequences of suchmutations have
often been conducted in bacterial models of complex I [58–61]. These
studies showed varied consequences at the level of complex I, ranging
from an assembly defect to a decrease in the enzyme activity. A differ-
ence in the sensitivity to inhibitors was also demonstrated, suggest-
ing an alteration of the quinone binding pocket [59,61]. Pathological
mutations inMT-ND1 leading to impairment in complex I activity (but
not assembly) could also suggest a defect in the regulation of the A/D
balance. The involvement of ND1 (andND3) on the A/D transition dem-
onstrated in this study raises questions as to the use of bacterial models
in the study of human point mutations found onMT-ND1 andMT-ND3.
Since the bacterial complex I does not display the A/D transition this
may be misleading for the study of the overall functional consequences
of such mutations, not at the level of the enzyme as such, but for global
consequences on the respiratory chain.
4.3. Potential mechanisms leading to the de-activation of
mitochondrial complex I
Deactivation results in rearrangements in ND3 as well as in ND1
subunits in the region of the quinone binding pocket and potentially
accounts for the labelling of ND3 (by SH-reagents and NHS esters) and
ND1 (by NHS esters) observed in the D-form only. It is possible that
deactivation of mitochondrial complex I leads to the disruption of the
enclosed quinone binding chamber due to a concerted structural rear-
rangement of these two crucial membrane subunits. The processes ofreduction of the physiological ubiquinone molecule and transmission
of the redox energy into putative proton translocating channel(s)
could then be disrupted. Interestingly, 49 kDa and PSST subunits were
equally labelled in both forms of complex I, suggesting rather selective
conformational change(s) in the membrane part of the enzyme at the
level of the entrance of the quinone binding cavity. It is tempting to
speculate that the initial slow turnover (kcat ~1–10 min−1) necessary
for activation of the D-form corresponds in fact to the formation of a
sealed chamber able to accommodate ubiquinone.
An alternative explanation is that a rearrangement of ND3 and
ND1 subunits during D to A transition is required for formation of a
mechanistic coupling link between the quinone reduction step and
conformationally driven proton translocation via antiporter-like
channels in the membrane. However, this is less likely since the
deactivation results in almost full inhibition of NADH:ubiquinone
reductase activity of the D-form.
Interestingly, it has been found that the addition of rotenone to amix-
ture of A- andD-forms in SMP (i) partially protects the A-form against de-
activation and (ii) partially converts the D-form to an A-like conforma-
tion. This was observed by measurement of the reverse electron transfer
activity after removal of rotenone with BSA. Rotenone could act (i) as a
clamp for the A-form of the enzyme and (ii) induce conformational
changes in the D-form similar to the transitory state so that the
enzyme-inhibitor complex can undergo activation without a turnover
[62].
Therefore, the rate of activation would be limited by the time
required for rearrangements of the enzyme structure, i.e. formation of
the pathway/binding site for the ubiquinonemolecule and/or reduction
of quinone at the terminal cluster N2.
5. Conclusions
Our results are in line with the known plasticity of the junction
region (Q-module) between the hydrophilic module that operates
the electron transfer from NADH to the terminal N2 FeS cluster
(N-module) and the proton pumping module (P-module) [63]. In-
deed, the formation of a subcomplex Iδ in the Y. lipolytica enzyme
after treatment with lauryl dimethylamine oxide showed that the
hydrophobic subunits of this connecting region (including ND1
and ND3) are the ﬁrst ones to be dissociated [64,65], suggesting a
difference in stability. The ﬂexibility of this region would then not
only be crucial for energy transduction, as previously suggested
[66–68], but also for the mechanism of conformational change
during A/D transition, as discussed in the present paper. These two
processes may however involve different types of structural rear-
rangement as it is unlikely that the A-form of complex I undergoes
extensive conformational change during steady-state catalytic turn-
over [4]. The activation/de-activation process would then probably
involve a higher degree of structural reorganisation compared to
that required for energy transduction during catalysis. The nature of
the driving force behind concerted conformational changes of at least
three subunits in the A/D transition (ND3, ND1 and 39 kDa) remains to
be answered.
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Fig. A2.Normalisedﬂuorescence intensities for every detectable subunit of complex I inA andD-forms after labellingwithNHS-esters. Fluorescence intensities are presented as percentage
of the total ﬂuorescence as described. SMP containing the A-form (black bars) and D-form (grey bars) of complex I were treated with both Cy3 and Cy5-NHS esters to overcome dye-
dependent effects.
Fig. A1. Collision induced dissociation (CID) spectra showing peptide TSPYECGFDPMGSAR of bovineND3 subunit with trioxidation on cysteine (+47.98474 Da), oxidation onmethionine
(+15.99492 Da), charge: +2, monoisotopic mass m/z: 841.32690 Da, mass deviation from theoretical−0.24 ppm, Mascot ion score: 61.
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